Agenus to Showcase Long-Term Survival Data for BOT+BAL Combo in Colorectal Cancer at SITC 2026

  • Agenus will present two posters at SITC 2026 on November 7, 2026, in Phoenix, Arizona.
  • One poster will highlight long-term survival data for BOT+BAL in refractory microsatellite-stable metastatic colorectal cancer (mCRC).
  • The second poster will showcase translational research on BOT+BAL combined with MiNK Therapeutics’ agenT-797 in a preclinical model of colorectal cancer liver metastases.
  • Approximately 1,300 patients have been treated with botensilimab and/or balstilimab in phase 1 and phase 2 clinical trials.

Agenus is positioning itself as a leader in immuno-oncology by showcasing long-term survival data for its BOT+BAL combination therapy. The focus on refractory mCRC, a challenging indication, highlights the potential for differentiation in a crowded market. The collaboration with MiNK Therapeutics on agenT-797 underscores the strategic importance of combination therapies in advancing cancer treatment.

Clinical Efficacy
How the long-term survival data for BOT+BAL in refractory mCRC will impact its regulatory and commercial prospects.
Combination Therapies
Whether the combination of BOT+BAL with agenT-797 can enhance tumor-cell killing in refractory colorectal cancer liver metastases.
Market Positioning
The pace at which Agenus can differentiate itself in the competitive immuno-oncology landscape with these data presentations.